Table 3. Qualitative performance of the BioFire Film Array Respiratory 2.1 Panel and Roche Cobas SARS-CoV-2 and Influenza A/B Assay (for Liat) during the Canadian Laboratory Network’s SARS-CoV-2 proficiency test schemes, May 2020 to June 2021.
| Platform | Sample ID | Sample G | Sample H | Sample I | Sample J | Sample K | Sample L | |
|---|---|---|---|---|---|---|---|---|
| BioFire® Film Array® Repiratory Panel 2.1 | Expected results | Detected SARS-CoV-2 | Detected Influenza A | Detected SARS-CoV-2 | No agent detected | Detected SARS-CoV-2 RSV |
Detected SARS-CoV-2 | |
| Sample concordance | 100% (20/20) |
100% (20/20) |
100% (20/20) |
100% (20/20) |
100% (20/20) |
100% (20/20) |
||
| Sample ID | Sample M | Sample N | Sample O | Sample P | Sample Q | Sample R | ||
| Expected results | Detected SARS-CoV-2 rhinovirus | Detected SARS-CoV-2 | Detected Influenza A | Detected SARS-CoV-2 | No agent detected | Detected SARS-CoV-2 Influenza B |
||
| Sample concordance | 100% (n=49/49) |
100% (n=49/49) |
100% (n=49/49) |
98.6% (n=48/49) |
100% (n=49/49) |
100% (n=49/49) |
||
| Overall concordance | 99.8% (413/414) | |||||||
| Roche Cobas® SARS-CoV-2 & Influenza A/B Assay (for Liat®) | Sample ID | Sample M | Sample N | Sample O | Sample P | Sample Q | Sample R | |
| Expected results | Detected SARS-CoV-2 | Detected SARS-CoV-2 | Detected Influenza A | Detected SARS-CoV-2 | No agent detected | Detected SARS-CoV-2 Influenza B |
||
| Sample concordance | 100% (n=9/9) |
100% (n=9/9) |
100% (n=9/9) |
100% (n=9/9) |
100% (n=9/9) |
100% (n=9/9) |
||
| Overall concordance | 100% (n=54/54) | |||||||
Abbreviations: RSV, respiratory syncycial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2